Multiple Myeloma

Latest News

November 7th 2023

Bispecific Therapies in RRMM: Teclistamab, Talquetamab, and Elranatamab Updates

By Sagar Lonial, MD, FACP, Luciano Costa, MD, PhD, Cesar Rodriguez, MD

Insight into the latest updates on three approved bispecific therapies in the context of relapsed and refractory multiple myeloma, including teclistamab, talquetamab, and elranatamab, discussing response rates, administration, and side effects.

Latest Videos

Educating Patients on Complications Associated with CAR T-Cell Therapy

A panel of 4 experts on multiple myeloma

Managing Cytopenias and HLH/MAS Following CAR T-Cell Therapy

Supportive Care Strategies for CAR T-Cell Therapy Recipients

Amrita Y. Krishnan, MD, and Binod Dhakal, MD

Clinical Implications of MajesTEC-1

Teclistamab Dosing and Adverse Event Prophylaxis Practices

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD

Study Design of the PERSEUS Trial

Frontline Treatment Landscape in Transplant-Eligible Patients with NDMM

Navigating Treatment Advancements and Recent Approvals in R/R Multiple Myeloma: Expert Insights

Advancements in the Treatment of Newly Diagnosed MM: Updates from the Phase 3 IMROZ Study

Monitoring Adverse Events Following CAR T-Cell Therapy

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

Video

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Video

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Video

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Zev A. Wainberg, MD; Manish A. Shah, MD, FASCO; Syma Iqbal, MD

Video

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Kentucky Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Munaf Alkadimi, MD

Video

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Indiana Oncology Society

Shaina Rozell, MD, MPH; Seth A. Wander, MD, PhD

In-Person Event

19th Annual New York GU Cancers Congress™

March 13-14, 2026

Video

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

Video

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

In-Person + Virtual Event

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

March 24, 2026

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

Video

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Video

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Video

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Misty D. Shields, MD, PhD; Rujul Parikh, MD

Video

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Charu Aggarwal, MD, MPH, FASCO; Yifan Tu, MD, PhD

Video

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Charu Aggarwal, MD, MPH, FASCO; Mo Ziari, MD

Video

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Zofia Piotrowska, MD, MHS; Shan Guo, MD

Video

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Misty D. Shields, MD, PhD; Michelle Ojemuyiwa, MD

In-Person + Virtual Event

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

February 19, 2026

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Video

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

More News

Jeffrey A. Zonder, MD, an expert on multiple myeloma

Cross Q&A: Retrospective Study of Patients With MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 3rd 2023

Experts in the field of multiple myeloma discuss data from a retrospective study on patients with multiple myeloma.

Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

ByCarolina D. Schinke, MD,Joselle Cook, M.B.B.S,Luciano Costa, MD, PhD,Binod Dhakal, MD, MS

November 2nd 2023

Dr Luciano Costa discusses treatment options for patients with multiple myeloma with early vs late relapse, noting that those with early aggressive relapse have limited options and often rapidly exhaust available therapies, emphasizing the need for newer agents like bispecific antibodies.

Patient Case Presentation: A 47-Year-Old Man With Multiple Myeloma

ByCarolina D. Schinke, MD,Joselle Cook, M.B.B.S,Luciano Costa, MD, PhD,Binod Dhakal, MD, MS

November 2nd 2023

Binod Dhakal, MD, presents the case of a young man with aggressive relapsed multiple myeloma to the panel for discussion.

Evolving Treatment Paradigms in Relapsed/Refractory Multiple Myeloma

BySagar Lonial, MD, FACP,Luciano Costa, MD, PhD,Cesar Rodriguez, MD,Donna Catamero, ANP-BC, OCN, CCRC

October 31st 2023

Join moderator Sagar Lonial, MD, FACP, and a panel of experts as they discuss recent updates in the management of relapsed and refractory multiple myeloma, exploring impact on clinical practice.

A panel of 4 experts on multiple myeloma seated at a long table

Treatment Decision-Making in Early-Relapse MM

ByAjai Chari, MD,Brea C. Lipe, MD,Binod Dhakal, MD, MS,Jeffrey V. Matous, MD

October 31st 2023

Expert perspectives on treatment decision-making in early-relapse multiple myeloma and the efficacy of CAR T-cell therapy.

Recent Data in the Management of Early-Relapse Multiple Myeloma

ByAjai Chari, MD,Brea C. Lipe, MD,Binod Dhakal, MD, MS,Jeffrey V. Matous, MD

October 31st 2023

A panel of oncologists give an overview of clinical trial data surrounding the management of early-relapse multiple myeloma.

Outcomes After Biochemical or Clinical Progression in Patients with MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 27th 2023

Jeffrey A. Zonder, MD, reviews data on patient outcomes following biochemical or clinical progression in multiple myeloma.

Jack Khouri, MD, an expert on multiple myeloma

Cross Q&A: Efficacy of CAR T-Cell Therapy in MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 27th 2023

The expert panel discusses the efficacy and durability of response of ciltacabtagene autoleucel in patients with multiple myeloma.

Preclinical Characterization of ISB 1342, a CD38 × CD3 T-Cell Engager for Relapsed/Refractory Multiple Myeloma

ByAmerican Society for Transplantation and Cellular Therapy

October 25th 2023

ISB 1342 has shown improved safety and efficacy for patients with relapsed/refractory multiple myeloma.

Mayo Clinic and UT Southwestern “Face Off” Over Multiple Myeloma and CML

ByONCOLOGY Staff

October 20th 2023

UT Southwestern and Mayo Clinic debated over current treatment options in chronic myeloid leukemia and multiple myeloma.

CARTITUDE-4: Cilta-Cel in Lenalidomide-Refractory MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 20th 2023

Jack Khouri, MD, discusses phase 3 results from the CARTITUDE-4 study investigating ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Andrew Kin, MD, an expert on multiple myeloma

Cross Q&A: Treatment Considerations for Ixa-Pom-Dex in Multiple Myeloma

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 20th 2023

Following a review of data from the ALLIANCE A061202 study, experts on multiple myeloma discuss treatment considerations for patients being treated with ixazomib, pomalidomide, and dexamethasone.

Fred Hutch and City of Hope “Face Off” on Ixazomib Vs Olverembatinib in CML and Multiple Myeloma

ByONCOLOGY Staff

October 19th 2023

Fred Hutch and City of Hope "Face Off" regarding presentations focusing on multiple myeloma and chronic myeloid leukemia.

Unmet Needs and Future Perspectives on Treating Patients With Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 18th 2023

Concluding their comprehensive discussion on treating patients with multiple myeloma, the expert panel discusses unmet needs and looks to the future of treatment.

Patient Profile 3: A 68-Year-Old With Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 18th 2023

The panel presents the case of a 68-year-old man with multiple myeloma and offers their initial impressions.

Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma

ByLudovic Saba, MD,Kevin S. Landau, MD,Silvia Bunting, MD,Chakra P. Chaulagain, MD

October 17th 2023

Investigators discussed the potential link between secondary pure red cell aplasia and subcutaneous daratumumab/hyaluronidase formulation for multiple myeloma.

ALLIANCE A061202: Ixazomib Plus Pomalidomide and Dexamethasone in Multiple Myeloma

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 13th 2023

Andrew Kin, MD, reviews data on the addition of ixazomib to pomalidomide and dexamethasone in patients with multiple myeloma who progressed on lenalidomide in the first line.

The host of Cancer Network's Face-Off program shown with an introductory slide

Team Introductions: MM Experts From Karmanos Cancer Institute and Cleveland Clinic

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 13th 2023

A panel of experts on multiple myeloma from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in multiple myeloma.

Patient Profile 2: A 75-Year-Old With Multiple Myeloma With Lytic Disease

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 11th 2023

Shared insights on the patient profile of a 75-year-old woman with multiple myeloma with confirmed lytic disease.

Patient Profile 1: A 70-Year-Old With Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 11th 2023

The expert panel presents the patient case of a 70-year-old man with multiple myeloma and discusses treatment decisions.

CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple Myeloma

ByVivian G. Oehler, MD,Andrew J. Cowan, MD,Rahul Banerjee, MD, FACP,Paul B. Koller, MD,Lawrence W. Liu, MD,Murali Janakiram, MD, MS

October 10th 2023

Panelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.

Looking Ahead in the Multiple Myeloma Treatment Landscape

ByMichael Rosenzweig, MD, MS,Ashwin Kashyap, MD,Neel Talwar, MD,Natasha Garg, DO, MS

October 4th 2023

Experts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.

Expert Perspectives on Quadruplet Therapy Regimens for Patients With Multiple Myeloma

ByMichael Rosenzweig, MD, MS,Ashwin Kashyap, MD,Neel Talwar, MD,Natasha Garg, DO, MS

October 4th 2023

The panel shares some personal experiences with treating patients with multiple myeloma with a quadruplet therapy regimen.

RedirecTT-1: Teclistamab Plus Talquetamab in Relapsed/Refractory MM

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 4th 2023

An overview of the RedirecTT-1 study investigating teclistamab plus talquetamab in patients with relapsed/refractory multiple myeloma.

Talquetamab for Patients With Relapsed/Refractory MM

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 4th 2023

Continuing discussion on bispecific antibodies, attention turns to talquetamab and the MonumenTAL-1 clinical trial for patients with relapsed/refractory multiple myeloma.

Multiple Myeloma

Latest News

Latest Videos

Educating Patients on Complications Associated with CAR T-Cell Therapy

Managing Cytopenias and HLH/MAS Following CAR T-Cell Therapy

Supportive Care Strategies for CAR T-Cell Therapy Recipients

Clinical Implications of MajesTEC-1

Teclistamab Dosing and Adverse Event Prophylaxis Practices

Study Design of the PERSEUS Trial

Frontline Treatment Landscape in Transplant-Eligible Patients with NDMM

Navigating Treatment Advancements and Recent Approvals in R/R Multiple Myeloma: Expert Insights

Advancements in the Treatment of Newly Diagnosed MM: Updates from the Phase 3 IMROZ Study

Monitoring Adverse Events Following CAR T-Cell Therapy

CME Content

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Kentucky Society of Clinical Oncology

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Indiana Oncology Society

19th Annual New York GU Cancers Congress™

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Proactive Adverse Event Management for HER2+ BTC Treatments

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

More News

Cross Q&A: Retrospective Study of Patients With MM

Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Patient Case Presentation: A 47-Year-Old Man With Multiple Myeloma

Evolving Treatment Paradigms in Relapsed/Refractory Multiple Myeloma

Treatment Decision-Making in Early-Relapse MM

Recent Data in the Management of Early-Relapse Multiple Myeloma

Outcomes After Biochemical or Clinical Progression in Patients with MM

Cross Q&A: Efficacy of CAR T-Cell Therapy in MM

Preclinical Characterization of ISB 1342, a CD38 × CD3 T-Cell Engager for Relapsed/Refractory Multiple Myeloma

Mayo Clinic and UT Southwestern “Face Off” Over Multiple Myeloma and CML

CARTITUDE-4: Cilta-Cel in Lenalidomide-Refractory MM

Cross Q&A: Treatment Considerations for Ixa-Pom-Dex in Multiple Myeloma

Fred Hutch and City of Hope “Face Off” on Ixazomib Vs Olverembatinib in CML and Multiple Myeloma

Unmet Needs and Future Perspectives on Treating Patients With Multiple Myeloma

Patient Profile 3: A 68-Year-Old With Multiple Myeloma

Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma

ALLIANCE A061202: Ixazomib Plus Pomalidomide and Dexamethasone in Multiple Myeloma

Team Introductions: MM Experts From Karmanos Cancer Institute and Cleveland Clinic

Patient Profile 2: A 75-Year-Old With Multiple Myeloma With Lytic Disease

Patient Profile 1: A 70-Year-Old With Multiple Myeloma

CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple Myeloma

Looking Ahead in the Multiple Myeloma Treatment Landscape

Expert Perspectives on Quadruplet Therapy Regimens for Patients With Multiple Myeloma

RedirecTT-1: Teclistamab Plus Talquetamab in Relapsed/Refractory MM

Talquetamab for Patients With Relapsed/Refractory MM

Trending on CancerNetwork

Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention

2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?

Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma

Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC